View in EDS HTML Full Text PDF Full Text

Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial.

Saved in:
Bibliographic Details
Title: Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial.
Authors: Zhang W; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China., Gong CF; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China., Huang JL; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China., Liu TY; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China., Sun YK; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China., Jiang ZC; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China., Qu W; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China., Yang L; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China., Xin Y; Medical Department, 3D Medicines Inc., Shanghai, 201114, China., Zhao FL; Medical Department, 3D Medicines Inc., Shanghai, 201114, China., Bai YZ; Medical Department, 3D Medicines Inc., Shanghai, 201114, China., Zhou AP; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. aiping_zhou@yeah.net.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 Nov 20; Vol. 74 (12), pp. 381. Date of Electronic Publication: 2025 Nov 20.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41264024
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhang+W%22">Zhang W</searchLink>; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.<br /><searchLink fieldCode="AU" term="%22Gong+CF%22">Gong CF</searchLink>; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.<br /><searchLink fieldCode="AU" term="%22Huang+JL%22">Huang JL</searchLink>; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.<br /><searchLink fieldCode="AU" term="%22Liu+TY%22">Liu TY</searchLink>; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.<br /><searchLink fieldCode="AU" term="%22Sun+YK%22">Sun YK</searchLink>; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.<br /><searchLink fieldCode="AU" term="%22Jiang+ZC%22">Jiang ZC</searchLink>; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.<br /><searchLink fieldCode="AU" term="%22Qu+W%22">Qu W</searchLink>; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.<br /><searchLink fieldCode="AU" term="%22Yang+L%22">Yang L</searchLink>; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.<br /><searchLink fieldCode="AU" term="%22Xin+Y%22">Xin Y</searchLink>; Medical Department, 3D Medicines Inc., Shanghai, 201114, China.<br /><searchLink fieldCode="AU" term="%22Zhao+FL%22">Zhao FL</searchLink>; Medical Department, 3D Medicines Inc., Shanghai, 201114, China.<br /><searchLink fieldCode="AU" term="%22Bai+YZ%22">Bai YZ</searchLink>; Medical Department, 3D Medicines Inc., Shanghai, 201114, China.<br /><searchLink fieldCode="AU" term="%22Zhou+AP%22">Zhou AP</searchLink>; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. aiping_zhou@yeah.net.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228605732%22">Cancer immunology, immunotherapy : CII</searchLink> [Cancer Immunol Immunother] 2025 Nov 20; Vol. 74 (12), pp. 381. <i>Date of Electronic Publication: </i>2025 Nov 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>8605732 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0851 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203407004%22">03407004 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41264024
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00262-025-04237-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 381
    Titles:
      – TitleFull: Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhang W
      – PersonEntity:
          Name:
            NameFull: Gong CF
      – PersonEntity:
          Name:
            NameFull: Huang JL
      – PersonEntity:
          Name:
            NameFull: Liu TY
      – PersonEntity:
          Name:
            NameFull: Sun YK
      – PersonEntity:
          Name:
            NameFull: Jiang ZC
      – PersonEntity:
          Name:
            NameFull: Qu W
      – PersonEntity:
          Name:
            NameFull: Yang L
      – PersonEntity:
          Name:
            NameFull: Xin Y
      – PersonEntity:
          Name:
            NameFull: Zhao FL
      – PersonEntity:
          Name:
            NameFull: Bai YZ
      – PersonEntity:
          Name:
            NameFull: Zhou AP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 11
              Text: 2025 Nov 20
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0851
          Numbering:
            – Type: volume
              Value: 74
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Cancer immunology, immunotherapy : CII
              Type: main
ResultId 1